__NUXT_JSONP__("/drugs/Abiraterone_Acetate", (function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o){return {data:[{drug:{slug:h,emaEpar:[{activeSubstance:b,conditionIndication:"Abiraterone Mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.",inn:b,marketingAuthorisationDate:"2021-08-20 00:00:00",marketingAuthorisationHolder:"Mylan Ireland Limited",medicineName:"Abiraterone Mylan",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fabiraterone-mylan"}],fdaDrugLabel:[{brand:c,indication:e,manufacturer:"MSN LABORATORIES PRIVATE LIMITED",splSetId:"0a84f388-a8b4-4065-93a6-1c663c99d265"},{brand:a,indication:f,manufacturer:"Teva Pharmaceuticals USA, Inc.",splSetId:"0b452d6a-c8fa-4668-9d34-60101a4129f0"},{brand:a,indication:f,manufacturer:i,splSetId:"2ac063f0-4177-c90f-27c3-e70e29689255"},{brand:c,indication:e,manufacturer:"BluePoint Laboratories",splSetId:"32f6b83d-c743-4934-9a20-1b5bf9f4eea3"},{brand:a,indication:"1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1)",manufacturer:"NorthStar Rx LLC",splSetId:"39434b24-bf64-f5c9-fbb6-b0d225099424"},{brand:d,indication:g,manufacturer:j,splSetId:"48ce18c7-5311-40cb-8903-104eb89b32e8"},{brand:a,indication:"1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with 1. Metastatic castration-resistant prostate cancer (CRPC). Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 )",manufacturer:"Major Pharmaceuticals",splSetId:"49809a29-6558-43a3-a347-5027de44aa41"},{brand:k,indication:"1 INDICATIONS AND USAGE ZYTIGA is indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 )",manufacturer:j,splSetId:"4e338e89-3cf2-48eb-b6e2-a06c608c6513"},{brand:d,indication:"1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).",manufacturer:"Rising Pharmaceuticals, Inc.",splSetId:"54ae5ef9-aea5-484a-a473-863b1397e206"},{brand:d,indication:"1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC). Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). (1)",manufacturer:"Wockhardt USA LLC.",splSetId:"76f9bb2f-4946-4391-9e7d-e4f867cf84db"},{brand:a,indication:"1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablet is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1) metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 )",manufacturer:"Dr. Reddys Laboratories Inc",splSetId:"7eda0d98-c2ba-c117-b757-1f566292e789"},{brand:a,indication:l,manufacturer:m,splSetId:"7f82d549-6654-1efd-e053-2991aa0aa28d"},{brand:a,indication:f,manufacturer:"Golden State Medical Supply, Inc.",splSetId:"8036d537-e94e-41ee-e053-2a91aa0ab635"},{brand:c,indication:e,manufacturer:"Novadoz Pharmaceuticals LLC",splSetId:"88d05db3-8bdc-47f1-bb00-6b4a71f98609"},{brand:d,indication:g,manufacturer:"CELLTRION USA, INC.",splSetId:"915b825a-2649-4079-9169-5e33a39c779d"},{brand:b,indication:g,manufacturer:i,splSetId:"9ce9d926-ef3a-4b22-a703-f49c18eb4e3d"},{brand:a,indication:n,manufacturer:"American Health Packaging",splSetId:"b5a22401-2a46-45d0-86ac-1fc6ecfb9a21"},{brand:"YONSA",indication:"1 INDICATIONS AND USAGE YONSA is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer. YONSA is a CYP17 inhibitor indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 )",manufacturer:"Sun Pharmaceutical Industries, Inc.",splSetId:"b8967e10-f768-47ce-ac9e-2324c8390132"},{brand:b,indication:"1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with • metastatic castration-resistant prostate cancer (CRPC). (1) • metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 )",manufacturer:"Glenmark Pharmaceuticals Inc., USA",splSetId:"ba32c453-a231-452a-a6d9-b3e57afb2e75"},{brand:c,indication:"1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with: Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with: metastatic castration-resistant prostate cancer (CRPC). (1) metastatic high-risk castration-sensitive prostate cancer (CSPC). (1)",manufacturer:"Hikma Pharmaceuticals USA Inc.",splSetId:"be29365a-ed25-44c0-9818-e9016dc95ba6"},{brand:o,indication:l,manufacturer:m,splSetId:"c1200e4e-c4f7-9067-e053-2a95a90af509"},{brand:a,indication:"1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). (1) metastatic high-risk castration-sensitive prostate cancer (CSPC). (1)",manufacturer:"Amneal Pharmaceuticals NY LLC",splSetId:"c9eb9b46-f847-40a8-802c-a51b40406d5a"},{brand:a,indication:n,manufacturer:"Mylan Institutional Inc.",splSetId:"caff75fb-9320-4f45-a3ac-d1755e679406"},{brand:a,indication:"1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with • metastatic castration-resistant prostate cancer (CRPC). ( 1 ) • metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 )",manufacturer:"Mylan Pharmaceuticals Inc.",splSetId:"fe02db79-fa04-441f-b514-70bd74af6624"}],id:h,nciThesaurus:{casRegistry:"154229-18-2",chebiId:"",chemicalFormula:"C26H33NO2",definition:"An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase\u002FC17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.",fdaUniiCode:"EM5OCB9YJ6",identifier:"C68845",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C147923"],synonyms:["17-(3-Pyridyl)-5,16-androstadien-3beta-acetate",o,a,"Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)-","BR9004","BR9004-1","CB7630","JNJ-212082","Yonsa",k,b]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAbiraterone_Acetate",extension:".json",createdAt:"2021-10-30T13:43:19.553Z",updatedAt:"2021-10-30T13:43:19.563Z"}}],fetch:{},mutations:void 0}}("Abiraterone Acetate","abiraterone acetate","Abiraterone","Abiraterone acetate","1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablet is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). (1) metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 )","1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 )","1 INDICATIONS AND USAGE Abiraterone acetate is indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 )","Abiraterone_Acetate","Apotex Corp.","Janssen Biotech, Inc.","Zytiga","1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). (1)","AvKARE","1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 )","ABIRATERONE ACETATE")));